We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01532375
Recruitment Status : Completed
First Posted : February 14, 2012
Last Update Posted : February 14, 2012
Information provided by:

February 10, 2012
February 14, 2012
February 14, 2012
October 2009
March 2010   (Final data collection date for primary outcome measure)
Visceral fat [ Time Frame: after 12 weeks of consumption ]
Same as current
No Changes Posted
  • Body Mass Index [ Time Frame: after 12 weeks of consumption ]
  • Subcutaneous fat [ Time Frame: after 12weeks ]
  • Triglyceride [ Time Frame: after 12week of consumption ]
  • Atherosclerosis index [ Time Frame: after 12weeks of consumption ]
  • Apolipoprotein [ Time Frame: after 12weeks of consumption ]
Same as current
Not Provided
Not Provided
Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults
Kochujang Decreases Visceral Fat and Improves Lipids Profiles
With the epidemic of obesity and diabetes growing around the world, Kochujang (KCJ) may be potentially effective in preventing and treating obesity and cardiovascular risks if proven in humans. However, human trial still have not been reported with KCJ supplementation. In the present study, we investigated the hypothesis that KCJ supplementation can be decrease the body fat and improve blood lipid profiles in overweight adults.

The aim of this study was to evaluate the efficacy of KCJ supplementation on anthropometric parameters, visceral fat/subcutaneous fat, and blood lipid profiles in overweight subjects.

Sixty overweight subjects with BMI >25 kg/m2 and waist-hip-ratio (WHR) ≥ 0.90 for men and ≥ 0.85 for women were randomly assigned to either KCJ supplement (n=30, 32 g/day) or placebo (n=30, 32 g/day) group for 12 weeks.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
  • Dietary Supplement: Kochujang
    Kochujang (32g/day) for 12weeks.
  • Dietary Supplement: placebo
    placebo(32g/day) for 12weeks
  • Experimental: Kochujang(32g)
    Intervention: Dietary Supplement: Kochujang
  • Placebo Comparator: placebo(32g)
    Intervention: Dietary Supplement: placebo
Cha YS, Kim SR, Yang JA, Back HI, Kim MG, Jung SJ, Song WO, Chae SW. Kochujang, fermented soybean-based red pepper paste, decreases visceral fat and improves blood lipid profiles in overweight adults. Nutr Metab (Lond). 2013 Feb 26;10(1):24. doi: 10.1186/1743-7075-10-24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI >25kg/m2 and 2)Waist-Hip Ratio (WHR): WHR> 0.90(male), WHR>0.85(female)

Exclusion Criteria:

  • lipid metabolic disorders
  • >10% changes in body weight in the past 3 months
  • Cardiovascular disease such as arrhythmia, heart failure, myocardial infarction, and wearing pacemaker
  • Allergy or hypersensitivity to any of the ingredients in the test products - History of reaction to any of the experimental products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
  • Participation in other clinical trials within the past 2 months
  • Abnormal hepatic liver function, renal disease such as acute

    • chronic renal failure, nephrotic syndrome
  • Use of anti-psychosis drug therapy within 2 months
  • Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
  • History of alcohol or substance abuse
  • Pregnancy or breastfeeding
Sexes Eligible for Study: All
19 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Chonbuk National University Hospital
Not Provided
Study Chair: Soo-Wan Chae, Ph.D, MD Chonbuk National University Hospital
Chonbuk National University Hospital
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP